{"id":910385,"date":"2025-11-14T17:29:21","date_gmt":"2025-11-14T22:29:21","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cineverse-reports-second-quarter-fiscal-year-2026-results\/"},"modified":"2025-11-14T17:29:21","modified_gmt":"2025-11-14T22:29:21","slug":"cineverse-reports-second-quarter-fiscal-year-2026-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cineverse-reports-second-quarter-fiscal-year-2026-results\/","title":{"rendered":"Cineverse Reports Second Quarter Fiscal Year 2026 Results"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Total Revenue of $12.4 Million<\/span><\/b>\n <\/p>\n

\n Direct Operating Margin of 58%, a 7% Improvement over Prior Year Quarter<\/b>\n <\/p>\n

\n
\n LOS ANGELES<\/span>
\n <\/span>, Nov. 14, 2025<\/span><\/span> \/PRNewswire\/ — Cineverse Corp. (“Cineverse” or the “Company”) (NASDAQ: CNVS)<\/b>, a next-generation entertainment studio, today announced its financial results for its second quarter ended September 30, 2025<\/span> (“Q2 FY 2026”):<\/p>\n

\n

\n
\n \"Courtesy
\n <\/a>\n <\/p>\n<\/p><\/div>\n

Total Revenue declined 3% year-over-year, primarily reflecting differences in the timing of revenue recognition for certain content licensing agreements. In the prior-year quarter, the Company recorded $1.6 million<\/span> from a Dog Whisperer<\/b> licensing agreement, while this quarter includes a recently signed $1.1 million<\/span> licensing deal for\u00a0The Toxic Avenger Unrated<\/b>\u00a0that will be recognized in future periods. Excluding these timing effects, performance across the Company’s core business lines continued to show solid underlying growth.<\/p>\n

Direct Operating Margin improved by 7% compared to the prior-year quarter. Net Loss and Adjusted EBITDA reflect increased SG&A driven by approximately $2.3 million<\/span> of marketing costs tied to the launch of\u00a0The Toxic Avenger Unrated<\/b>\u00a0and ongoing investments to support the expansion of Cineverse’s theatrical slate and the build-out of its Technology group’s business development, product, and sales capabilities.\u00a0The Toxic Avenger Unrated<\/b>\u00a0is performing strongly in ancillary markets and is projected to generate an IRR of over 40%.<\/p>\n

Subsequent to quarter end, Cineverse announced another key addition to its theatrical slate. In late 2026, the Company will reissue the 20th anniversary edition of\u00a0Pan’s Labyrinth<\/b>, the acclaimed Guillermo del Toro<\/span> film that won three Academy Awards and over 100 international honors. Cineverse will return to the Cannes<\/span> Film Festival next May for a special anniversary presentation to kick off the marketing campaign for a Fall 2026 wide release.<\/p>\n

\n
\n Q2 FY 2026 Highlights <\/u>
\n <\/b>
\n
\n (all comparisons are to the prior year fiscal quarter ended September 30, 2024<\/span>, or Q2 FY 2025): <\/u>
\n <\/i>\n <\/p>\n

Total quarterly revenue was $12.4 million<\/span> versus $12.7 million<\/span> in the prior-year quarter, a 3% decrease, driven by gains in streaming and digital distribution, as well as theatrical sales.<\/p>\n